Journal: Nutrition Research and Practice

Article Title: Modulatory effects of Hizikia fusiformis on the dopaminergic system in a neonatal habenular lesion-induced attention-deficit hyperactivity disorder-like rodent model

doi: 10.4162/nrp.2026.20.1.31

Figure Lengend Snippet: (A) The bar graph indicates the percentage of VEH in HF-induced MAP2 expression. (B, C) These bar graphs are similar to graph (A); however, they show the expression of NF (B) and SYP (C). Protein expression was analyzed using analysis of variance and Bonferroni post-hoc test. Statistical significance was set at P < 0.05. HF, Hizikia fusiformis ; MAP2, microtubule-associated protein 2; NF, neurofilament; SYP, synaptophysin; VEH, vehicle.

Article Snippet: The following were the primary antibodies used: mouse monoclonal anti-synaptophysin (SYP; catalog #: S5768; Sigma-Aldrich), rabbit polyclonal anti-tyrosine hydroxylase (TH; catalog #: E-AB-33093; Elabscience, Houston, TX, USA), mouse monoclonal neurofilament (NF; catalog #: sc-20012; Santa Cruz Biotechnology, Dallas, TX, USA), rabbit polyclonal anti-DAT (catalog #: PA1-4656; Invitrogen, Waltham, MA, USA), mouse monoclonal anti-DRD2 (catalog #: sc-5303; Santa Cruz Biotechnology), rabbit polyclonal anti-DRD1 (catalog #: E-AB-31152; Elabscience), mouse monoclonal anti-DRD3 (catalog #: sc-136170; Santa Cruz Biotechnology), rabbit polyclonal anti-DRD5 (catalog #: MBS2516950; MyBioSource, San Diego, CA, USA), mouse monoclonal anti-microtubule-associated protein 2 (MAP2; catalog #: sc-32791; Santa Cruz Biotechnology), and rabbit polyclonal anti-DRD4 (catalog #: E-AB-31153; Elabscience).

Techniques: Expressing

Journal: Molecular Biomedicine

Article Title: Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes

doi: 10.1186/s43556-025-00398-w

Figure Lengend Snippet: Effect of introducing point mutations on the biological activity of FGF1. a Serum-starved NIH 3T3 cells were treated with 10 ng/mL FGF1 variants for 15 min in the presence of heparin (10 U/mL). Activation of the downstream cascade was detected by immunoblotting using the following antibodies: anti-phospho-FRS2 (pFRS2) and anti-phospho-ERK1/2 (pERK1/2). Anti-ERK1/2 and anti-vinculin antibodies were used to confirm equal loading. Representative results are shown (n ≥ 3). The vertical lines in the last WB panel show the deleted wells. The original membranes, together with the method of trimming, are presented in Fig. S2. Densitometric analysis of pERK/ERK is presented in Fig. S3. b Effect of 20-h FGF1 variants stimulation (20 ng/mL) in the presence of 10 U/mL heparin on glucose uptake by 3T3-L1 adipocytes. Data are presented as mean ± SEM, n = 4. Statistical significance: * p ≤ 0.05; ** p ≤ 0.01 and *** p ≤ 0.001

Article Snippet: The following primary antibodies were used: anti-phospho-FGFR (Tyr653/Tyr654) (pFGFR) (#06–1433) from Millipore, anti-tubulin (#T6557) from Sigma-Aldrich, anti-FGFR1 (FGFR1) (#9740), anti-phospho-p44/42 (Thr202/Tyr204) MAP kinase (pERK1/2) (#9101), anti-p44/42 MAP kinase (ERK1/2) (#9102), anti-phospho-FRS2α (Tyr196) (pFRS2) (#3864), anti-vinculin (#13901), anti-phospho-PLCγ1 (Tyr783) (pPLCγ) (#14,008), anti-PLCγ1 (#5690), anti-Glut1 (#73,015) and anti-FGF1 (#3139) from Cell Signaling Technology.

Techniques: Activity Assay, Activation Assay, Western Blot

Journal: Molecular Biomedicine

Article Title: Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes

doi: 10.1186/s43556-025-00398-w

Figure Lengend Snippet: Impaired activation of signaling pathways by FGF1 variants due to reduced affinity for the FGFR1 (IIIc) receptor. a Serum-starved NIH 3T3 cells were stimulated with 10 ng/mL FGF1 variants in the presence of heparin (10 U/mL) for 15 min, and activation of downstream signaling cascades was detected by immunoblotting using the following antibodies: anti-phospho-FGFR (pFGFR), anti-phospho-PLCγ (pPLCγ), anti-phosphoFRS2 (pFRS2), anti-phospho-ERK1/2 (pERK1/2). Anti-ERK1/2, anti-FGFR1, anti-PLCγ and anti-γTubulin antibodies were used to confirm equal loading. Representative results are shown. Densitometric analysis is presented as mean ± SEM, n = 3/4. Statistical significance: * p ≤ 0.05; ** p ≤ 0.01 and *** p ≤ 0.001. b BLI analysis of the affinity of FGF1 variants for FGFR1-Fc (IIIc isoform). FGFR1-Fc was immobilized on a Protein A sensor and its interactions (association and dissociation) with selected FGF1 mutants were analyzed in the concentration range of 100–800 nM. Curves obtained by global fitting are marked in red. Representative results are shown (n ≥ 3). The equilibrium dissociation constant (K D ) was calculated from the saturation binding curve

Article Snippet: The following primary antibodies were used: anti-phospho-FGFR (Tyr653/Tyr654) (pFGFR) (#06–1433) from Millipore, anti-tubulin (#T6557) from Sigma-Aldrich, anti-FGFR1 (FGFR1) (#9740), anti-phospho-p44/42 (Thr202/Tyr204) MAP kinase (pERK1/2) (#9101), anti-p44/42 MAP kinase (ERK1/2) (#9102), anti-phospho-FRS2α (Tyr196) (pFRS2) (#3864), anti-vinculin (#13901), anti-phospho-PLCγ1 (Tyr783) (pPLCγ) (#14,008), anti-PLCγ1 (#5690), anti-Glut1 (#73,015) and anti-FGF1 (#3139) from Cell Signaling Technology.

Techniques: Activation Assay, Protein-Protein interactions, Western Blot, Concentration Assay, Binding Assay